

# Estrid V Hgdall

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9426346/estrid-v-hogdall-publications-by-year.pdf>  
**Version:** 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

173 papers	6,698 citations	43 h-index	77 g-index
179 ext. papers	7,988 ext. citations	5.8 avg, IF	5.12 L-index

#	Paper	IF	Citations
173	RNA profiles reveal signatures of future health and disease in pregnancy.. <i>Nature</i> , <b>2022</b> ,	50.4	9
172	Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review).. <i>Molecular and Clinical Oncology</i> , <b>2022</b> , 16, 29	1.6	0
171	Genomic Sub-Classification of Ovarian Clear Cell Carcinoma Revealed by Distinct Mutational Signatures. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
170	Oncomine[Comprehensive Assay v3 vs. Oncomine[Comprehensive Assay Plus. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
169	Gene expression profile association with poor prognosis in epithelial ovarian cancer patients. <i>Scientific Reports</i> , <b>2021</b> , 11, 5438	4.9	2
168	Next Generation Sequencing Technology in the Clinic and Its Challenges. <i>Cancers</i> , <b>2021</b> , 13,	6.6	7
167	DNA Methylation in Ovarian Tumors-a Comparison Between Fresh Tissue and FFPE Samples. <i>Reproductive Sciences</i> , <b>2021</b> , 28, 3212-3218	3	0
166	Prognostic impact of histological review of high-grade endometrial carcinomas in a large Danish cohort. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2021</b> , 479, 507-514	5.1	1
165	MicroRNA characteristics in epithelial ovarian cancer. <i>PLoS ONE</i> , <b>2021</b> , 16, e0252401	3.7	1
164	Integrated microRNA and mRNA signatures associated with overall survival in epithelial ovarian cancer. <i>PLoS ONE</i> , <b>2021</b> , 16, e0255142	3.7	1
163	Noncoding RNA (ncRNA) Profile Association with Patient Outcome in Epithelial Ovarian Cancer Cases. <i>Reproductive Sciences</i> , <b>2021</b> , 28, 757-765	3	2
162	The somatic mode: doing good in targeted cancer therapy. <i>New Genetics and Society</i> , <b>2021</b> , 40, 178-198	1.9	4
161	Incidents in Molecular Pathology: Frequency and Causes During Routine Testing. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2021</b> , 145, 1270-1279	5	1
160	Early Laboratory Diagnosis of COVID-19 by Antigen Detection in Blood Samples of the SARS-CoV-2 Nucleocapsid Protein. <i>Journal of Clinical Microbiology</i> , <b>2021</b> , 59, e0100121	9.7	3
159	Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement. <i>Clinica Chimica Acta</i> , <b>2021</b> , 522, 152-157	6.2	1
158	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. <i>Gynecologic Oncology</i> , <b>2020</b> , 158, 702-709	4.9	5
157	DNA sequencing of cytopathologically inconclusive EUS-FNA from solid pancreatic lesions suspicious for malignancy confirms EUS diagnosis. <i>Endoscopic Ultrasound</i> , <b>2020</b> , 9, 37-44	3.6	6

156	Exome sequencing of 22 genes using tissue from patients with biliary tract cancer. <i>Apmis</i> , <b>2020</b> , 128, 3-9	3.4	3
155	Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 1034-1042	3.5	2
154	MicroRNA Biomarkers in IBD-Differential Diagnosis and Prediction of Colitis-Associated Cancer. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	22
153	Evaluation of analytical accuracy of HER2 status in patients with breast cancer: Comparison of HER2 GPA with HER2 IHC and HER2 FISH. <i>Apmis</i> , <b>2020</b> , 128, 573-582	3.4	1
152	Annexin A2 and S100A10 as Candidate Prognostic Markers in Epithelial Ovarian Cancer. <i>Anticancer Research</i> , <b>2019</b> , 39, 2475-2482	2.3	7
151	The prevalence of EBV and CMV DNA in epithelial ovarian cancer. <i>Infectious Agents and Cancer</i> , <b>2019</b> , 14, 7	3.5	9
150	Methylation and ovarian cancer: Can DNA methylation be of diagnostic use?. <i>Molecular and Clinical Oncology</i> , <b>2019</b> , 10, 323-330	1.6	19
149	High-Throughput Sequencing-Based Investigation of Viruses in Human Cancers by Multienrichment Approach. <i>Journal of Infectious Diseases</i> , <b>2019</b> , 220, 1312-1324	7	7
148	The prospect of discovering new biomarkers for ovarian cancer based on current knowledge of susceptibility loci and genetic variation (Review). <i>International Journal of Molecular Medicine</i> , <b>2019</b> , 44, 1599-1608	4.4	2
147	Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass. <i>PLoS ONE</i> , <b>2019</b> , 14, e0225249	3.7	13
146	Optimized Biobanking Procedures for Preservation of RNA in Tissue: Comparison of Snap-Freezing and RNAlater-Fixation Methods. <i>Biopreservation and Biobanking</i> , <b>2019</b> , 17, 562-569	2.1	4
145	Ovarian Clear Cell Carcinoma: From Morphology to Molecular Biology. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2019</b> , 27, 631-636	1.9	0
144	Adenoid cystic carcinomas of the salivary gland, lacrimal gland, and breast are morphologically and genetically similar but have distinct microRNA expression profiles. <i>Modern Pathology</i> , <b>2018</b> , 31, 1211-1225	9.8	20
143	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , <b>2018</b> , 93, 307-320	6.4	14
142	Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer. <i>Acta Oncologica</i> , <b>2018</b> , 57, 1057-1062	3.2	15
141	The PRKD1 E710D hotspot mutation is highly specific in separating polymorphous adenocarcinoma of the palate from adenoid cystic carcinoma and pleomorphic adenoma on FNA. <i>Cancer Cytopathology</i> , <b>2018</b> , 126, 275-281	3.9	18
140	MicroRNA dysregulation in adenoid cystic carcinoma of the salivary gland in relation to prognosis and gene fusion status: a cohort study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2018</b> , 473, 329-340	5.1	16
139	Effect of inhibition of CBP-coactivated $\beta$ -catenin-mediated Wnt signalling in uremic rats with vascular calcifications. <i>PLoS ONE</i> , <b>2018</b> , 13, e0201936	3.7	8

138	Evidence of No Association Between Human Papillomavirus and Breast Cancer. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 209	5.3	7
137	Deep sequencing of human papillomavirus positive loco-regionally advanced oropharyngeal squamous cell carcinomas reveals novel mutational signature. <i>BMC Cancer</i> , <b>2018</b> , 18, 640	4.8	9
136	Digital image analysis of pan-cytokeratin stained tumor slides for evaluation of tumor budding in pT1/pT2 colorectal cancer: Results of a feasibility study. <i>Pathology Research and Practice</i> , <b>2018</b> , 214, 1273-1281 <sup>11</sup>	3.4	11
135	Early metastatic colorectal cancers show increased tissue expression of miR-17/92 cluster members in the invasive tumor front. <i>Human Pathology</i> , <b>2018</b> , 80, 231-238	3.7	10
134	Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction. <i>Oncolmunology</i> , <b>2018</b> , 7, e1412029	7.2	21
133	FP375EFFECT OF WNT-INHIBITION ON ESTABLISHED VASCULAR CALCIFICATION IN UREMIC RATS. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, i159-i159	4.3	
132	Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer. <i>PLoS ONE</i> , <b>2018</b> , 13, e0207319	3.7	26
131	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. <i>British Journal of Cancer</i> , <b>2017</b> , 116, 524-535	8.7	18
130	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 2422-2435	7.5	18
129	Risk factors for brain metastases in patients with metastatic colorectal cancer. <i>Acta Oncologica</i> , <b>2017</b> , 56, 639-645	3.2	20
128	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , <b>2017</b> , 49, 680-691	36.3	190
127	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. <i>British Journal of Cancer</i> , <b>2017</b> , 116, 1223-1228	8.7	11
126	History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. <i>Cancer Causes and Control</i> , <b>2017</b> , 28, 469-486	2.8	19
125	Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. <i>Cancer Causes and Control</i> , <b>2017</b> , 28, 459-468	2.8	13
124	Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies. <i>American Journal of Epidemiology</i> , <b>2017</b> , 185, 8-20	3.8	44
123	Genetic and Functional Drivers of Diffuse Large B-Cell Lymphoma. <i>Cell</i> , <b>2017</b> , 171, 481-494.e15	56.2	499
122	Searching for new biomarkers in ovarian cancer patients: Rationale and design of a retrospective study under the Mermaid III project. <i>Contemporary Clinical Trials Communications</i> , <b>2017</b> , 8, 167-174	1.8	9
121	Demographic, Clinical, and Prognostic Factors of Ovarian Clear Cell Adenocarcinomas According to Endometriosis Status. <i>International Journal of Gynecological Cancer</i> , <b>2017</b> , 27, 1804-1812	3.5	8

120	Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer. <i>PLoS ONE</i> , <b>2017</b> , 12, e0174300	3.7	9
119	History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 1063-1069	8.7	11
118	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2017</b> , 26, 1470-1473	4	8
117	Inflammatory Bowel Disease and Small Bowel Cancer Risk, Clinical Characteristics, and Histopathology: A Population-Based Study. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 1900-1907.e2	6.9	34
116	Continuing rise in oropharyngeal cancer in a high HPV prevalence area: A Danish population-based study from 2011 to 2014. <i>European Journal of Cancer</i> , <b>2017</b> , 70, 75-82	7.5	86
115	Adjustment of serum HE4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 108213-108222	3.3	5
114	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , <b>2016</b> , 141, 386-401	4.9	15
113	Investigating intra-tumor heterogeneity and expression gradients of miR-21, miR-92a and miR-200c and their potential of predicting lymph node metastases in early colorectal cancer. <i>Experimental and Molecular Pathology</i> , <b>2016</b> , 101, 187-196	4.4	9
112	HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer. <i>Apmis</i> , <b>2016</b> , 124, 1038-1045	3.4	10
111	Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT). <i>Gynecologic Oncology</i> , <b>2016</b> , 142, 50-53	4.9	26
110	A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study. <i>Tumor Biology</i> , <b>2016</b> , 37, 12619-12626	2.9	15
109	Approaches to the detection of ovarian cancer. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2016</b> , 245, S49-53	2	4
108	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , <b>2016</b> , 6, 1052-67	24.4	104
107	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , <b>2016</b> , 7, 12675	17.4	53
106	The prognostic value of polycomb group protein B-cell-specific moloney murine leukemia virus insertion site 1 in stage II colon cancer patients. <i>Apmis</i> , <b>2016</b> , 124, 541-6	3.4	2
105	Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance. <i>Oncology Letters</i> , <b>2016</b> , 11, 393-398	2.6	9
104	Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2016</b> , 25, 780-90	4	8
103	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. <i>Cancer Epidemiology</i> , <b>2016</b> , 41, 71-9	2.8	17

102	SOX9 expression predicts relapse of stage II colon cancer patients. <i>Human Pathology</i> , <b>2016</b> , 52, 38-46	3.7	17
101	Intra-tumor heterogeneity of microRNA-92a, microRNA-375 and microRNA-424 in colorectal cancer. <i>Experimental and Molecular Pathology</i> , <b>2016</b> , 100, 125-31	4.4	14
100	Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 134-7	8.7	55
99	(GT)n Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation. <i>PLoS ONE</i> , <b>2016</b> , 11, e0168210	3.7	5
98	Outcome of cetuximab plus irinotecan in relation to RAS and BRAF mutational status in patients with colorectal cancer prior treated with a fluoropyrimidine, oxaliplatin and irinotecan.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e15115-e15115	2.2	
97	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , <b>2016</b> , 45, 884-95	7.8	45
96	Demographic Clinical and Prognostic Factors of Primary Ovarian Adenocarcinomas of Serous and Clear Cell Histology-A Comparative Study. <i>International Journal of Gynecological Cancer</i> , <b>2016</b> , 26, 82-90	3.5	17
95	Current status on microRNAs as biomarkers for ovarian cancer. <i>Apmis</i> , <b>2016</b> , 124, 337-55	3.4	25
94	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , <b>2016</b> , 53, 800-811	5.8	121
93	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , <b>2016</b> , 135, 741-56	6.3	18
92	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , <b>2016</b> , 45, 1619-1630	7.8	77
91	Remodeling of the Tumor Microenvironment Predicts Increased Risk of Cancer in Postmenopausal Women: The Prospective Epidemiologic Risk Factor (PERF I) Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2016</b> , 25, 1348-55	4	9
90	Hyperplastic polyps of the colon and rectum - reclassification, BRAF and KRAS status in index polyps and subsequent colorectal carcinoma. <i>Apmis</i> , <b>2015</b> , 123, 298-304	3.4	8
89	Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma. <i>Experimental Hematology</i> , <b>2015</b> , 43, 534-6	3.1	
88	Clinical implications of intestinal stem cell markers in colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2015</b> , 14, 63-71	3.8	25
87	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 5264-76	12.9	24
86	Topoisomerase-1 gene copy aberrations are frequent in patients with breast cancer. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 2000-6	7.5	12
85	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , <b>2015</b> , 24, 5955-64	5.6	48



84	Tetranectin positive expression in tumour tissue leads to longer survival in Danish women with ovarian cancer. Results from the TMAlovaTovarian cancer study. <i>Apmis</i> , <b>2015</b> , 123, 401-9	3.4	6
83	A novel monoclonal antibody to a defined peptide epitope in MUC16. <i>Glycobiology</i> , <b>2015</b> , 25, 1172-82	5.8	15
82	Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2901-7	2.2	200
81	The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population. <i>Apmis</i> , <b>2015</b> , 123, 108-15	3.4	45
80	MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability. <i>BMC Cancer</i> , <b>2015</b> , 15, 1024	4.8	26
79	HPV genotype distribution in older Danish women undergoing surgery due to cervical cancer. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , <b>2015</b> , 94, 1262-8	3.8	8
78	KRAS and BRAF mutations in anal carcinoma. <i>Apmis</i> , <b>2015</b> , 123, 53-9	3.4	16
77	Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 2039-46	1.9	9
76	The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics. <i>Gynecologic Oncology</i> , <b>2015</b> , 136, 205-11	4.9	26
75	Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 652-7	12.9	107
74	Coffee, tea, and caffeine consumption and risk of epithelial ovarian cancer and borderline ovarian tumors: Results from a Danish case-control study. <i>Acta Oncologica</i> , <b>2015</b> , 54, 1144-51	3.2	17
73	PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma. <i>Oncotarget</i> , <b>2015</b> , 6, 32266-78	3.3	21
72	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. <i>Human Genetics</i> , <b>2014</b> , 133, 481-97	6.3	21
71	Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status. <i>Cellular Oncology (Dordrecht)</i> , <b>2014</b> , 37, 215-27	7.2	56
70	High specificity but low sensitivity of mutation-specific antibodies against EGFR mutations in non-small-cell lung cancer. <i>Modern Pathology</i> , <b>2014</b> , 27, 1590-8	9.8	17
69	Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. <i>Molecular Nutrition and Food Research</i> , <b>2014</b> , 58, 2023-35	5.9	8
68	Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1812-7	2.2	123
67	Serum YKL-40 and uterine artery Doppler -- a prospective cohort study, with focus on preeclampsia and small-for-gestational-age. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , <b>2014</b> , 93, 817-24	3.8	3

66	miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan. <i>PLoS ONE</i> , <b>2014</b> , 9, e99886	3.7	54
65	Human papillomavirus in head and neck squamous cell carcinoma of unknown primary is a common event and a strong predictor of survival. <i>PLoS ONE</i> , <b>2014</b> , 9, e110456	3.7	37
64	HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors: a systematic review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2014</b> , 23, 2285-94	4.5	49
63	miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer. <i>Frontiers in Oncology</i> , <b>2014</b> , 4, 207	5.3	21
62	The nationwide Danish CancerBiobank: Future possibilities.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e22196e22196	2.2	22196
61	Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium. <i>BMC Cancer</i> , <b>2013</b> , 13, 28	4.8	23
60	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 853-62	21.7	248
59	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , <b>2013</b> , 45, 362-70, 370e1-2	36.3	267
58	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , <b>2013</b> , 45, 371-84, 384e1-2	36.3	422
57	Pelvic inflammatory disease and risk of invasive ovarian cancer and ovarian borderline tumors. <i>Cancer Causes and Control</i> , <b>2013</b> , 24, 1459-64	2.8	23
56	Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. <i>Cancer Causes and Control</i> , <b>2013</b> , 24, 989-1004	2.8	69
55	SUVmax of 18FDG PET/CT as a predictor of high-risk endometrial cancer patients. <i>Gynecologic Oncology</i> , <b>2013</b> , 129, 298-303	4.9	39
54	Development of a metastatic fluorescent Lewis Lung carcinoma mouse model: identification of mRNAs and microRNAs involved in tumor invasion. <i>Gene</i> , <b>2013</b> , 517, 72-81	3.8	12
53	MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer - a multicenter prospective comparative study. <i>Gynecologic Oncology</i> , <b>2013</b> , 128, 300-8	4.9	146
52	Bacterial infection as a likely cause of adverse reactions to polyacrylamide hydrogel fillers in cosmetic surgery. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 56, 1438-44	11.6	44
51	Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the TMALOVATovarian cancer study. <i>Apmis</i> , <b>2013</b> , 121, 1177-86	3.4	8
50	Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization for Low and High Throughput HER2 Genetic Testing. <i>International Journal of Breast Cancer</i> , <b>2013</b> , 2013, 368731	2.3	7
49	Diagnostic accuracy of risk of malignancy index in predicting complete tumor removal at primary debulking surgery for ovarian cancer patients. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , <b>2013</b> , 92, 721-6	3.8	2



48	HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET). <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , <b>2013</b> , 92, 1313-1322	3.8	48
47	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , <b>2013</b> , 4, 1628	17.4	124
46	Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. <i>International Journal of Epidemiology</i> , <b>2013</b> , 42, 579-89	7.8	122
45	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. <i>Nature Communications</i> , <b>2013</b> , 4, 1627	17.4	85
44	Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 307, 382-90	27.4	427
43	Use of analgesic drugs and risk of ovarian cancer: results from a Danish case-control study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , <b>2012</b> , 91, 1094-102	3.8	16
42	Use of dairy products, lactose, and calcium and risk of ovarian cancer - results from a Danish case-control study. <i>Acta Oncologica</i> , <b>2012</b> , 51, 454-64	3.2	21
41	BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. <i>OncoImmunology</i> , <b>2012</b> , 1, 1476-1483	7.2	68
40	Genome-wide association study for ovarian cancer susceptibility using pooled DNA. <i>Twin Research and Human Genetics</i> , <b>2012</b> , 15, 615-623	2.2	8
39	Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas. <i>Pancreas</i> , <b>2012</b> , 41, 759-66	2.6	52
38	Positron emission tomography/computed tomography predictors of overall survival in stage IIIC/IV ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2012</b> , 22, 1163-9	3.5	26
37	Circulating antinuclear antibodies in patients with pelvic masses are associated with malignancy and decreased survival. <i>PLoS ONE</i> , <b>2012</b> , 7, e30997	3.7	10
36	A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burden. <i>PLoS ONE</i> , <b>2012</b> , 7, e33100	3.7	17
35	High expression of miR-21 in tumor stroma correlates with increased cancer cell proliferation in human breast cancer. <i>Apmis</i> , <b>2011</b> , 119, 663-73	3.4	71
34	Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. <i>International Journal of Cancer</i> , <b>2011</b> , 128, 2063-74	7.5	49
33	Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer. <i>Acta Oncologica</i> , <b>2011</b> , 50, 415-9	3.2	31
32	Assessment of hepatocyte growth factor in ovarian cancer mortality. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2011</b> , 20, 1638-48	4	30
31	Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2011</b> , 20, 1028-31	4	

30	The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 3742-50	12.9	45
29	Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium. <i>PLoS ONE</i> , <b>2011</b> , 6, e19642	3.7	4
28	Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium. <i>PLoS ONE</i> , <b>2011</b> , 6, e20703	3.7	20
27	Molecular signatures of thyroid follicular neoplasia. <i>Endocrine-Related Cancer</i> , <b>2010</b> , 17, 691-708	5.7	25
26	Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2010</b> , 19, 1822-30	4	22
25	Serum tetranectin is a significant prognostic marker in ovarian cancer patients. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , <b>2010</b> , 89, 190-8	3.8	6
24	Serum tetranectin as a preoperative indicator for postoperative complications in Danish ovarian cancer patients. <i>Gynecologic Oncology</i> , <b>2010</b> , 117, 446-50	4.9	1
23	Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis. <i>Proteomics - Clinical Applications</i> , <b>2010</b> , 4, 304-14	3.1	14
22	Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients. <i>Proteomics - Clinical Applications</i> , <b>2010</b> , 4, 940-52	3.1	22
21	Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40. <i>Apmis</i> , <b>2009</b> , 117, 518-25	3.4	29
20	Risk of ovarian cancer in women with first-degree relatives with cancer. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , <b>2009</b> , 88, 449-56	3.8	13
19	Feasibility of serodiagnosis of ovarian cancer by mass spectrometry. <i>Analytical Chemistry</i> , <b>2009</b> , 81, 1907-13	7.13	12
18	A proteomics panel for predicting optimal primary cytoreduction in stage III/IV ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2009</b> , 19, 1535-8	3.5	4
17	Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery. <i>International Journal of Gynecological Cancer</i> , <b>2009</b> , 19, 600-4	3.5	42
16	Gene expression profiles as prognostic markers in women with ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2009</b> , 19, 1205-13	3.5	12
15	Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer. <i>PLoS ONE</i> , <b>2009</b> , 4, e5983	3.7	33
14	BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 3761-7	12.9	77
13	Cancer antigen 125 and prognosis. <i>Current Opinion in Obstetrics and Gynecology</i> , <b>2008</b> , 20, 4-8	2.4	51

12	Accuracy of self-reported family history of cancer in a large case-control study of ovarian cancer. <i>Cancer Causes and Control</i> , <b>2008</b> , 19, 469-79	2.8	23
11	Sample handling for mass spectrometric proteomic investigations of human urine. <i>Proteomics - Clinical Applications</i> , <b>2008</b> , 2, 1184-93	3.1	9
10	The diagnostic value of PET/CT for primary ovarian cancer--a prospective study. <i>Gynecologic Oncology</i> , <b>2007</b> , 105, 145-9	4.9	128
9	Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2007</b> , 16, 1160-6	4	82
8	Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2007</b> , 847, 30-7	3.2	61
7	Smoking and overweight: negative prognostic factors in stage III epithelial ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2006</b> , 15, 798-803	4	46
6	The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. <i>Cancer Research</i> , <b>2006</b> , 66, 10630-6	10.1	157
5	Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer. <i>Apmis</i> , <b>2006</b> , 114, 359-63	3.4	18
4	Sample handling for mass spectrometric proteomic investigations of human sera. <i>Analytical Chemistry</i> , <b>2005</b> , 77, 5114-23	7.8	127
3	Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. <i>Archives of Internal Medicine</i> , <b>2004</b> , 164, 2253-9		81
2	The variation of risk estimates through pregnancy in second trimester maternal serum screening for Down syndrome. <i>Prenatal Diagnosis</i> , <b>2002</b> , 22, 385-7	3.2	10
1	Identification of bacteria using two degenerate 16S rDNA sequencing primers. <i>Microbiological Research</i> , <b>1999</b> , 154, 23-6	5.3	17